GLP-1 drugs, including Wegovy, Zepbound, and Foundayo, help patients lose weight by mimicking a hormone that makes the body ...

The life sciences industry is entering a period in which artificial intelligence is increasingly becoming part of how ...

Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

A global coalition of patient advocates, industry and non-profit organisations has called on governments to strengthen action on chronic obstructive pulmonary ...

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

Shinhan Securities says Olix could become big pharma's only ALK7 obesity drug licensing candidate as rivals report first ...

Note: This article is written based on publicly available information and market data as of September 15, 2026.IntroductionThe TV commercials for "Sedes" when you have pain, or the vitamin supplement ...